Goldman Sachs Lifts Price Target On Pfizer (PFE), Keeps Top Rating
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Price: $25.69 -0.85%
Rating Summary:
13 Buy, 20 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 51
Rating Summary:
13 Buy, 20 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 51
Join SI Premium – FREE
Earlier, Goldman Sachs raised its price target on Conviction Buy List-rated Pfizer (NYSE: PFE) from $23 to $25, citing room for upside.
For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.
Shares of Pfizer closed at $21.57 yesterday.
For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.
Shares of Pfizer closed at $21.57 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BRF - Brasil Foods S.A. (BRFS3:BZ) (BRFS) PT Raised to BRL19 at Itau BBA
- Jones Trading Starts Achieve Life Sciences (ACHV) at Buy, 'see significant opportunity for a branded drug'
- Johnson & Johnson (JNJ) PT Lowered to $155 at Stifel
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Goldman Sachs Conviction Buy List, Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
